Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has announced a partnership with Japan’s peptide-based therapeutics and diagnostics specialist, Peptidream (TYO: 4587). The collaboration aims to discover and develop potential first-in-class peptide-drug conjugates (PDCs) for the targeted delivery of radioisotopes against specific disease targets.
Details of the Partnership
Under the terms of the agreement, Peptidream will be responsible for early preclinical development of the PDCs. Promising candidates will then be handed over to Genentech for further development, clinical trials, and commercialization. As part of the deal, Peptidream will receive an upfront payment of USD 40 million, with the potential for milestone payments up to USD 1 billion. Additionally, Peptidream will retain rights to the products in Japan and will receive ex-Japan sales royalties.
History of Collaboration
The collaboration between Genentech and Peptidream began in 2015 with a multi-target project. This was followed by the licensing of Peptidream’s discovery platform in the same year and an expansion of the partnership in 2018. The ongoing relationship between the two companies demonstrates a shared commitment to advancing innovative therapeutics in the field of peptide-drug conjugates.-Fineline Info & Tech
